secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lunai Bioworks Inc. (LNAI)
CIK:        0001527728
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001731122-24-000877
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Renovaro signs MoU with Amsterdam UMC to form joint cancer immunotherapy company
--------------------------------------------------------------------------------

- Signed MoU to establish Newco in Netherlands for personalized cancer immunotherapy.
- Combines Renovaro's proprietary dendritic vaccine tech with Amsterdam UMC's immunomodulatory expertise.
- Newco to be headquartered in Amsterdam; clinical activities may move there.
- Final commitments subject to due diligence and approval from both executive boards.
- No financial terms or deal value disclosed in the press release.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527728/000173112224000877/0001731122-24-000877-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527728/000173112224000877/e5707_8-k.htm
  HTML page:      https://secwatch.observer/filing/0001731122-24-000877

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer